These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
    Author: Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sié P.
    Journal: J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646.
    Abstract:
    Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.
    [Abstract] [Full Text] [Related] [New Search]